On December 27, 2023, Spyre Therapeutics, Inc. closed the transaction. The transaction included participation from 30 investors. The company paid finders fee of $10,800,000 in the transaction.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
32.7 USD | -0.85% | -10.35% | +50.35% |
May. 15 | Spyre Therapeutics, Inc. Announces Board Changes | CI |
May. 13 | Wells Fargo Adjusts Price Target on Spyre Therapeutics to $40 From $35, Maintains Overweight Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+50.35% | 1.33B | |
+9.96% | 118B | |
+10.30% | 106B | |
-11.38% | 23.4B | |
-1.69% | 22.1B | |
-10.23% | 18.34B | |
-41.92% | 16.59B | |
-15.46% | 15.97B | |
+6.79% | 14.03B | |
+17.88% | 11.67B |
- Stock Market
- Equities
- SYRE Stock
- News Spyre Therapeutics, Inc.
- Spyre Therapeutics, Inc. announced that it has received $180 million in funding from a group of investors